Skip to main content

Advertisement

SpringerLink
Log in

Simplifying HAART: the Role of Two-Drug Therapy

  • HIV Medicine (CJ Yoon, Section editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion Statement

Since 1996, triple-drug combinations consisting of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus either a ritonavir-boosted protease inhibitor, a non-nucleoside reverse transcriptase inhibitor or recently, an integrase inhibitor have been considered the standard of care for treatment of HIV-infected individuals. As patients’ life expectancy has increased, an increasing rate of comorbidities has been reported. Cumulative toxicity and cost have become an important concern motivating new research exploring alternative antiretroviral treatment strategies. In different clinical trials, NRTI-sparing regimens have been explored in order to preserve effectiveness while reducing toxicity and potential costs. However, to date, class-sparing regimens have shown lower effectiveness than standard triple-drug therapy regimens in antiretroviral-naïve patients. On the other hand, the use of dual therapy without certain nucleosides, such as tenofovir or zidovudine, was explored in the GARDEL trial consisting of the use of ritonavir-boosted lopinavir and lamivudine. This is the only large trial showing non-inferiority of dual therapy at 48 and 96 weeks compared to triple therapy. The improved potency, tolerability and durability, and fewer reported toxicities, of newer drugs with a higher resistance barrier paved the way for the evaluation of other class-sparing strategies, including monotherapy and dual therapies that are being applied as initial therapy or as a switch strategy in patients virologically suppressed on triple-drug regimens. The aim of the dual strategy is to achieve and maintain viral suppression, improve immunologic recovery, minimize short- and long-term adverse effects, and thereby improve adherence and potentially reduce costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA. 2016;316:191. International guidelines produced by a recognized expert panel that updates first-line regimen based on the latest clinical evidence. the last evidence.

    Article  PubMed  PubMed Central  Google Scholar 

  2. •• Gulick RM. Choosing initial antiretroviral therapy: current recommendations for initial therapy and newer or investigational agents. Top Antivir Med. 2015;23:128–31. Comprehensive review of factors taking into account when initiating ARV therapy.

    PubMed  Google Scholar 

  3. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy. JAIDS. 2004;36:808–16.

    PubMed  Google Scholar 

  4. Boyle B, Lackey P, Morales-Ramirez J. Early assessment of adherence and treatment satisfaction differences in a QD versus a BID or more frequently dosed HAART regimen. In: 11th International Congress on Infectious Diseases. Cancun, Mexico; 2004. Poster 12.026.

  5. •• Derache A, Shin H-S, Balamane M, White E, Israelski D, Klausner JD, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLoS One. 2015;10, e0117430. Study showing that DNA can be detected in a quarter of aviremic patients, and a good genotype concordance between DNA and RNA in viremic patients, which suggests DNA genotyping might be used for testing suppressed patients before switching.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396–407.

    Article  CAS  PubMed  Google Scholar 

  7. Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–707.

    Article  PubMed  Google Scholar 

  8. •• Baril J-G, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. PLoS One. 2016;11, e0148231. Systematic review of the current evidence including 13 trials among suppressed patients. Some studies showed benefit, but others could not. More research and longer follow-up is needed before recommending a specific regimen for simplifying HIV-suppressed patients.

    Article  PubMed  PubMed Central  Google Scholar 

  9. • Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise. Lancet Infect Dis. 2014;14:572–80. First large randomized trial, supported through an Investigator-Initiated Research Grant, showing non-inferiority of dual therapy compared to triple-therapy regimen.

    Article  CAS  PubMed  Google Scholar 

  10. Arribas JR, Girard P-M, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a random. Lancet Infect Dis. 2015;15:785–92.

    Article  CAS  PubMed  Google Scholar 

  11. Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D’Avino A, Borghetti A, et al. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. J Antimicrob Chemother. 2015;70:1843–9.

    Article  CAS  PubMed  Google Scholar 

  12. Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, et al. Simplification to atazanavir/ritonavir + lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc. 2014;17:19808.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D’Ettorre G, Antinori A, et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017. doi:10.1093/jac/dkw557.

    Google Scholar 

  14. Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, et al. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15:775–84.

    Article  CAS  PubMed  Google Scholar 

  15. Pulido F, Ribera E, Lagarde M, Perez-Valero I, Santos J, Iribarren JA, et al. Non-inferiority of dual-therapy with DRV/r plus 3TC versus triple-therapy with DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral supression: 48-weeks results of the DUAL-GESIDA 8014 trial. In: International Congress of Drug Therapy in HIV Infection. 2016:Abstract 033.

  16. van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, et al. Brief report: switch to ritonavir-boosted atazanavir plus raltegravir in virologically suppressed patients with HIV-1 infection: a randomized pilot study. J Acquir Immune Defic Syndr. 2016;71:538–43.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gantner P, Koeppel C, Partisani M, Batard M-L, Bernard-Henry C, Cheneau C, et al. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scand J Infect Dis. 2014;46:838–45.

    Article  CAS  PubMed  Google Scholar 

  18. Ruane P, Wolfe P. Dual maintenance therapy with raltegravir 400 mg BID with atazanavir 400 mg QD in patients with no prior PI resistance and intolerance to other ATV regimens: follow up report. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston; 2010

  19. Cohen C, Green J, Olivet H, Khanlou H, Burman W, Corales RB, et al. A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID. In: 11th International Congress on Drug Therapy in HIV Infection. 2012.

  20. Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, et al. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. J Clin Virol. 2017;87:30–6.

    Article  CAS  PubMed  Google Scholar 

  21. Gantner P, Bani-Sadr F, Garraffo R, Roger P-M, Treger M, Jovelin T, et al. Dat’AIDS cohort: switch to ritonavir-boosted versus unboosted atazanavir plus raltegravir dual-drug therapy leads to similar efficacy and safety outcomes in clinical practice. PLoS One. 2016;11, e0164240.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retrovir. 2012;28:1196–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, et al. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013;8, e73639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Calza L, Danese I, Magistrelli E, Colangeli V, Manfredi R, Bon I, et al. Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors. HIV Clin Trials. 2016;17:38–47.

    Article  CAS  PubMed  Google Scholar 

  25. Latini A, Fabbiani M, Borghi V, Sterrantino G, Giannetti A, Lorenzini P, et al. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis. 2016;16:401.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Raffi F, Babiker AG, Richert L, Molina J-M, George EC, Antinori A, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51.

    Article  CAS  PubMed  Google Scholar 

  27. Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, et al. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther. 2016. doi:10.3851/IMP3095.

    Google Scholar 

  28. Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007;21:325–33.

    Article  CAS  PubMed  Google Scholar 

  29. Negredo E, Moltó J, Burger D, Côté H, Miró O, Ribalta J, et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). J Acquir Immune Defic Syndr. 2005;38:47–52.

    Article  CAS  PubMed  Google Scholar 

  30. Portilla J, Arazo P, Crusells J, Pérez-Martínez L, Martínez-Madrid O, Boix V, et al. Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study. J Int AIDS Soc. 2014;17:19803.

    PubMed  PubMed Central  Google Scholar 

  31. Maggiolo F, Di Filippo E, Valenti D, Ortega PS, Callegaro A. NRTI sparing therapy in virologically controlled HIV-1 infected subjects: results of a controlled, randomized trial (probe). J Acquir Immune Defic Syndr. 2016;72:46–51.

    Article  CAS  PubMed  Google Scholar 

  32. Foca M, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, et al. Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults. Pediatr Infect Dis J. 2016;35:e271–4.

    Article  PubMed  Google Scholar 

  33. Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, et al. Maraviroc, as a switch option, in HIV-1 infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first N(t)RTI + PI/r regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study (MARCH). Clin Infect Dis. 2016;63:1–31.

    Article  Google Scholar 

  34. Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, et al. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther. 2014;19:117–23.

    Article  CAS  PubMed  Google Scholar 

  35. Calza L, Magistrelli E, Colangeli V, Borderi M, Conti M, Mancini R, et al. Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir/boosted protease inhibitor to raltegravir plus nevirapine: a pilot study. Antivir Ther. 2015;20:217–24.

    Article  Google Scholar 

  36. Calin R, Paris L, Simon A, Peytavin G, Wirden M, Schneider L, et al. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther. 2012;17:1601–4.

    Article  CAS  PubMed  Google Scholar 

  37. Monteiro P, Perez I, Laguno M, Martinez-Rebollar M, Gonzalez-Cordon A, Lonca M, et al. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. J Antimicrob Chemother. 2014;69:742–8.

    Article  CAS  PubMed  Google Scholar 

  38. Casado JL, Bañón S, Rodriguez MA, Moreno A, Moreno S. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients. Antivir Res. 2015;113:103–6.

    Article  CAS  PubMed  Google Scholar 

  39. Calin R, Valantin M, Simon A, Paris L, Tubiana R, Schneider L. Raltegravir/etravirine dual therapy as a virologically safe treatment option in suppressed HIV-1- infected patients without previous NNRTI failure. In 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Kuala Lumpur; 2013.

  40. Calza L, Magistrelli E, Colangeli V, Manfredi R, Borderi M, Rossi N, et al. Dual raltegravir etravirine combination as maintenance regimen in virologically suppressed HIV-1 infected patients. AIDS Res Hum Retrovir. 2017. doi:10.1089/AID.2016.0291.

    Google Scholar 

  41. Capetti AF, Sterrantino G, Cossu MV, Orofino G, Barbarini G, De Socio GV, et al. Switch to dolutegravir plus rilpivirine dual therapy in cART-experienced subjects: an observational cohort. PLoS One. 2016;11, e0164753.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Katlama C, Assoumou L, Valantin M-A, Soulié C, Duvivier C, Chablais L, et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother. 2014;69:1648–52.

    Article  CAS  PubMed  Google Scholar 

  43. Pradat P, Durant J, Brochier C, Trabaud M-A, Cottalorda-Dufayard J, Izopet J, et al. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. J Antimicrob Chemother. 2016. doi:10.1093/jac/dkw273.

    PubMed  Google Scholar 

  44. Cahn P, Rolon M, Figueroa M, Gun A, Patterson P, Sued O: Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial. In: 21th International Conference on AIDS. Durban; 2016.

  45. Gubavu C, Prazuck T, Niang M, Buret J, Mille C, Guinard J, et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother. 2016;71:1046–50.

    Article  CAS  PubMed  Google Scholar 

  46. Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D’Avino A, Mondi A, et al. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. J Antimicrob Chemother. 2016;71:2359–61.

    Article  CAS  PubMed  Google Scholar 

  47. •• Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016;62:784–91. Mathematical modeling suggesting important savings in the US if switching suppressed HIV patients to DTG + 3TC, and changing all the first-line regimen to this dual one.

    Article  PubMed  Google Scholar 

  48. Margolis D, Podzamczer D, Stellbrink HJ, Lutz T, Angel J, Richmond G, et al. Cabotegravir + rilpivirine as long-acting maintenance therapy: LATTE2 week 48 results. In: 21st International Conference on AIDS. 2016: Durban South Africa.

  49. •• Carr A, Hoy J, Pozniak A. The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior? PLoS Med. 2012;9, e1001240. Critical view of the reasons for which investigators should propose switch studies in HIV-positive patients.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research Department, Fundación Huésped, Buenos Aires, Argentina

    Maria José Rolón MD, Omar Sued MD & Pedro Cahn MD, PhD

Authors
  1. Maria José Rolón MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omar Sued MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pedro Cahn MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pedro Cahn MD, PhD.

Ethics declarations

Conflict of Interest

María José Rolón and Omar Sued declare that they have no conflicts of interest. Pedro Cahn declares research grants from Abbvie, Merck, and ViiV Healthcare and is a member of advisory boards of Merck and ViiV Healthcare.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on HIV Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rolón, M.J., Sued, O. & Cahn, P. Simplifying HAART: the Role of Two-Drug Therapy. Curr Treat Options Infect Dis 9, 250–261 (2017). https://doi.org/10.1007/s40506-017-0125-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-017-0125-9

Keywords

Search

Navigation